Careers in Israel
Careers in USA
Board of Directors
Scientific Advisory Board
Johns Hopkins University
Mount Sinai Hospital
Annual and Quarterly Reports
Therapeutic product discovery
In the information age
The next wave in immuno-oncology
May 22, 2019
Compugen to Present at the Jefferies 2019 Healthcare Conference
May 20, 2019
Compugen Reports First Quarter 2019 Results
Research and Development
Our optimized process for predictive discovery of novel drug targets
Our ongoing Phase 1 study of COM701, a first-in-class antibody targeting PVRIG, a novel ICP target
Compugen, FROM CODE TO CURE
CGEN-15029 is the internal designation for PVRIG, a novel B7/CD28-like immune checkpoint target candidate discovered by...
CGEN-15137 is the internal designation for TIGIT, an immune checkpoint in the B7/CD28 family which has recently gained broad...
CGEN-15001T is a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen. CGEN-15001T is expressed in various subpopulations of immune cells...
CGEN-15001 is our lead program for autoimmune diseases. It is a first-in-class therapeutic candidate of a novel inhibitory checkpoint pathway, with the potential to restore...
Jun 04, 2019
Compugen Presentation at the Jefferies 2019 Healthcare Conference
New York, NY
May 20, 2019
Compugen First Quarter 2019 Conference Call
Jun 01, 2019
COM701 Phase 1 Study Trial-in-Progress Poster Presentation, ASCO 2019 Annual Meeting
Click here for more info about partnering with Compugen